Bharat Biotech- No more Vaccine Shortage...?!
India has not yet approved the use of the nasal vaccine 'BBV154' developed by the Hyderabad-based company.
Bharat Biotech has sought permission from India's drug regulator for the Phase III study of an anti-covid vaccine given through the nose.
The company has sought permission to study this vaccine as a booster dose for people who have been fully vaccinated.
India has not yet approved the use of the nasal vaccine 'BBV154' developed by the Hyderabad-based company.
Meanwhile, the Drug Controller General of india (DCGI) has allowed the use of the 'Covaxin' vaccine being produced by the company for a period of 12 months from manufacture.
Sources in hyderabad said, "The company has applied to the DCGI and is awaiting its approval. This nasal vaccine will be given to those who have already taken both doses of the vaccines.
A government official in the capital New delhi confirmed the receipt of the application from the company and said that Bharat Biotech has increased safety after giving "BBV154" and "BBV152" as the third (booster) dose to the already vaccinated participants.
and has sought permission for a Phase III study to evaluate immunogenicity.
DCGI in august allowed the company to conduct Phase II clinical trials of the nasal vaccine.
DBT had said that according to the company's report, doses of the vaccine were given to healthy participants in the first phase of clinical trials and none showed serious adverse effects.
Meanwhile, Bharat Biotech said in a release that DCGI has allowed the use of the 'Covaxin' vaccine for 12 months from the period of its manufacture.